Publication:
Enhancement of lymphangiogenesis in vitro via the regulations of HIF-1 α expression and nuclear translocation by deoxyshikonin

dc.contributor.authorPrangsaengtong O.
dc.contributor.authorPark J.Y.
dc.contributor.authorInujima A.
dc.contributor.authorIgarashi Y.
dc.contributor.authorShibahara N.
dc.contributor.authorKoizumi K.
dc.date.accessioned2021-04-05T03:33:04Z
dc.date.available2021-04-05T03:33:04Z
dc.date.issued2013
dc.date.issuedBE2556
dc.description.abstractThe objectives of this study were to determine the effects of deoxyshikonin on lymphangiogenesis. Deoxyshikonin enhanced the ability of human dermal lymphatic microvascular endothelial cells (HMVEC-dLy) to undergo time-dependent in vitro cord formation. Interestingly, an opposite result was observed in cells treated with shikonin. The increased cord formation ability following deoxyshikonin treatment correlated with increased VEGF-C mRNA expression to higher levels than seen for VEGF-A and VEGF-D mRNA expression. We also found that deoxyshikonin regulated cord formation of HMVEC-dLy by increasing the HIF-1α mRNA level, HIF-1α protein level, and the accumulation of HIF-1α in the nucleus. Knockdown of the HIF-1α gene by transfection with siHIF-1α decreased VEGF-C mRNA expression and cord formation ability in HMVEC-dLy. Deoxyshikonin treatment could not recover VEGF-C mRNA expression and cord formation ability in HIF-1α knockdown cells. This indicated that deoxyshikonin induction of VEGF-C mRNA expression and cord formation in HMVEC-dLy on Matrigel occurred mainly via HIF-1α regulation. We also found that deoxyshikonin promoted wound healing in vitro by the induction of HMVEC-dLy migration into the wound gap. This study describes a new effect of deoxyshikonin, namely, the promotion of cord formation by human endothelial cells via the regulation of HIF-1α. The findings suggest that deoxyshikonin may be a new drug candidate for wound healing and treatment of lymphatic diseases. © 2013 Orawin Prangsaengtong et al.
dc.format.mimetypeapplication/pdf
dc.identifier.citationEvidence-based Complementary and Alternative Medicine. Vol 2013, No. (2013), p.-
dc.identifier.doi10.1155/2013/148297
dc.identifier.issn1741427X
dc.identifier.other2-s2.0-84877964031
dc.identifier.urihttps://hdl.handle.net/20.500.14740/6655
dc.rights.holderมหาวิทยาลัยศรีนครินทรวิโรฒ
dc.subject.otherDeoxyshikonin
dc.subject.otherHypoxia inducible factor 1alpha
dc.subject.otherMessenger RNA
dc.subject.otherShikonin derivative
dc.subject.otherUnclassified drug
dc.subject.otherVasculotropin C
dc.subject.otherArticle
dc.subject.otherCell function
dc.subject.otherControlled study
dc.subject.otherDrug mechanism
dc.subject.otherEndothelium cell
dc.subject.otherGene expression regulation
dc.subject.otherGene silencing
dc.subject.otherGene translocation
dc.subject.otherGenetic transfection
dc.subject.otherHuman
dc.subject.otherHuman cell
dc.subject.otherIn vitro study
dc.subject.otherLymphangiogenesis
dc.subject.otherPriority journal
dc.subject.otherProtein expression
dc.titleEnhancement of lymphangiogenesis in vitro via the regulations of HIF-1 α expression and nuclear translocation by deoxyshikonin
dc.typeArticle
dspace.entity.typePublication
swu.datasource.scopushttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84877964031&doi=10.1155%2f2013%2f148297&partnerID=40&md5=d06d5e7699423d7a8aa64b5e2a799cdc

Files